Zoetis
ZTS
Market cap $69.4B

155.19 USD

-1.43

0.91%

At close Aug 25, 4:00 PM EDT

After hours

155.19

+0.00

0.00%

1 day

-0.91%

5 days

1.48%

1 month

2.02%

3 months

-6.66%

6 months

-7.92%

Year to date

-4.56%

1 year

-14.52%

5 years

-2.14%

10 years

264.64%

About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Employees: 13,800

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,429 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

7% more funds holding in top 10

Funds holding in top 10: 14 [Q1] → 15 (+1) [Q2]

2.21% more ownership

Funds ownership: 92.22% [Q1] → 94.43% (+2.21%) [Q2]

10% more first-time investments, than exits

New positions opened: 149 | Existing positions closed: 136

6% more call options, than puts

Call options by funds: $196M | Put options by funds: $184M

1% more repeat investments, than reductions

Existing positions increased: 721 | Existing positions reduced: 717

4% less capital invested

Capital invested by funds: $67.9B [Q1] → $65.4B (-$2.53B) [Q2]

2% less funds holding

Funds holding: 1,863 [Q1] → 1,829 (-34) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$155

0%

upside

Avg. target

$177

14%

upside

High target

$215

39%

upside

3 analyst ratings

1 positive

33%

2 neutral

67%

0 negative

0%

Piper Sandler David Westenberg	39%upside $215	Overweight Maintained	11 Aug 2025
Leerink Partners Daniel Clark	0%downside $155	Market Perform Downgraded	17 Jul 2025
Stifel Jonathan Block	3%upside $160	Hold Downgraded	18 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 23 articles about ZTS published over the past 30 days

Zoetis: Why I Decided To Invest In The Stock

Zoetis remains the global leader in animal health, with 68% of revenue from companion animals. Q2 results showed 8% organic sales growth and 15% adjusted earnings growth. Librela sales in the U.S. declined 16% due to reported side effect concerns.

Zoetis: Why I Decided To Invest In The Stock

The Motley Fool

Got $1,000? 3 Dividend Stocks to Buy and Hold Forever

Right now is not a good time in the healthcare sector. Various companies across the space are well below highs while the broader stock market chugs along at all-time highs.

Got $1,000? 3 Dividend Stocks to Buy and Hold Forever

Zoetis Announces Pricing of $1.85 Billion of Senior Notes

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billion aggregate principal amount of 5.000% senior notes due 2035, in an underwritten public offering. Zoetis intends to use the net proceeds to repay the principal of (i) its 4.500% senior notes due 2025 in the aggregate principal amount of $750 million, (ii) its 5.4.

Zoetis Announces Pricing of $1.85 Billion of Senior Notes

The Motley Fool

If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today

Ah, 10 years ago. It was 2015, and selfie sticks and hoverboards were all over.

If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today

Zacks Investment Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

The Motley Fool

2 Stocks to Buy With $5,000 and Hold for a Decade

It can be tempting to try to predict market movements so you buy low and sell high, but it's notoriously difficult to execute successfully. Even if you succeed once or twice, replicating that often enough to build a profitable portfolio that stands the test of time is next to impossible.

2 Stocks to Buy With $5,000 and Hold for a Decade

Top 50 High-Quality Dividend Stocks For August 2025

My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated future return of at least 10%, with 10 of these also appearing potentially undervalued by my Free Cash Flow model. Top highlighted stocks like MKTX, RACE, RMD, MSCI, and TTC combine strong free cash flow growth, attractive valuations, and double-digit return estimates.

Top 50 High-Quality Dividend Stocks For August 2025

Zacks Investment Research

Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term

CNBC Television

Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs

Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.

Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs

Zacks Investment Research

ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised

Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.

ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised

See News Rankings

Charts implemented using Lightweight Charts™